Attached files
file | filename |
---|---|
EX-99 - PRESS RELEASE - CORCEPT THERAPEUTICS INC | corcepttherapeutics.htm |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the |
Date of Report: March 06, 2017
(Date
of earliest event reported)
Corcept Therapeutics
(Exact name of
registrant as specified in its charter)
CA
(State or
other jurisdiction
of incorporation) 000-50679
(Commission
File Number) 74-0487658
(IRS Employer
Identification Number)
149 Commonwealth Drive
(Address of
principal executive offices)
94025
(Zip Code)
650-327-3270
(Registrant's
telephone number, including area code)
Not Applicable
(Former Name or Former
Address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
- o Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Item 2.02. Results of Operations and Financial
Condition Item 7.01. Regulation FD Disclosure Item 9.01. Financial Statements and Exhibits (d) Exhibits
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. |
Dated: March 06, 2017 |
CORCEPT THERAPEUTICS
By: /s/ Charles Robb
|
| |
Exhibit No. | Description |
99.1 | Press Release of Corcept Therapeutics dated March 06, 2017 |